Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/24/2025

Duration of Dual Antiplatelet Therapy After Stent in Acute Myocardial Infarction

Standard DAPT Duration for AMI Patients

  • The American College of Cardiology and American Heart Association recommend that P2Y12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) combined with aspirin should be given for at least 12 months after stent implantation in AMI patients, regardless of whether a bare metal stent (BMS) or drug-eluting stent (DES) was used 1, 2
  • The American College of Cardiology recommends a daily aspirin dose of 81 mg (range 75-100 mg) as part of DAPT 1, 2
  • For patients with AMI treated with medical therapy alone (without revascularization) or with fibrinolytic therapy, the American College of Cardiology recommends that DAPT should also be continued for at least 12 months 2, 3

Choice of P2Y12 Inhibitor

  • The American College of Cardiology suggests that in AMI patients treated with stent implantation, it is reasonable to use ticagrelor in preference to clopidogrel for maintenance P2Y12 inhibitor therapy 1, 2
  • For patients without high bleeding risk and without history of stroke or TIA, the American College of Cardiology recommends that prasugrel is a reasonable choice over clopidogrel 1, 2
  • The American College of Cardiology recommends that prasugrel should not be administered to patients with prior history of stroke or TIA due to increased bleeding risk 1, 2

Special Considerations for DAPT Duration

  • In AMI patients who have tolerated DAPT without bleeding complications and who are not at high bleeding risk, the American College of Cardiology suggests that continuation of DAPT beyond 12 months may be reasonable 1, 2, 3
  • In AMI patients treated with DES who develop high bleeding risk, are at high risk of severe bleeding complications, or develop significant overt bleeding, the American College of Cardiology recommends that discontinuation of P2Y12 therapy after 6 months may be reasonable 1, 2, 3

DAPT After CABG in AMI Patients

  • The American College of Cardiology recommends that in AMI patients being treated with DAPT who undergo coronary artery bypass grafting (CABG), P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after the AMI 1, 2
  • Before CABG, the American College of Cardiology recommends that P2Y12 inhibitors should be discontinued to decrease perioperative bleeding risk (at least 3 days for ticagrelor, 5 days for clopidogrel, and 7 days for prasugrel) 4, 5

Risk-Benefit Assessment

  • The American College of Cardiology recommends that the decision regarding DAPT duration requires balancing thrombotic and bleeding risks 6, 7

Common Pitfalls to Avoid

  • The American College of Cardiology recommends that failing to consider both bleeding and ischemic risks when determining DAPT duration should be avoided 6, 7
  • The American College of Cardiology recommends that prematurely discontinuing DAPT within the first 12 months after AMI without compelling reasons should be avoided 1, 2
  • The American College of Cardiology recommends that using prasugrel in patients with history of stroke or TIA should be avoided 1, 2
  • The American College of Cardiology recommends that not adjusting aspirin dose to the recommended 75-100 mg daily when used as part of DAPT should be avoided 1, 2

DAPT Continuation Beyond 12 Months Post-STEMI

Rationale for Extended DAPT Duration

  • The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend P2Y12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) combined with aspirin for at least 12 months after drug-eluting stent (DES) implantation in STEMI patients, with a Class IIb recommendation for continuation beyond 12 months in patients who have tolerated DAPT without bleeding complications and are not at high bleeding risk 8, 9, 10, 11
  • Patients with complex multivessel disease, including left main involvement, are at high ischemic risk and may benefit from extended DAPT, according to the ACC/AHA guidelines 8, 11
  • The absence of bleeding complications and lack of contraindications such as prior bleeding on DAPT, coagulopathy, or oral anticoagulant use support the continuation of DAPT beyond 12 months 8, 9, 11

Optimal Aspirin Dosing

  • The ACC/AHA guidelines recommend maintaining aspirin at 81 mg daily (acceptable range 75-100 mg) as part of DAPT, which provides equivalent antiplatelet efficacy while minimizing bleeding risk compared to higher doses 8, 9, 11, 12

Alternative P2Y12 Inhibitor Considerations

  • Ticagrelor may be a reasonable alternative to clopidogrel for maintenance P2Y12 inhibitor therapy in ACS patients treated with stent implantation, with a Class IIa recommendation from the ACC/AHA guidelines 8, 9, 10

Duration of Extended DAPT

  • The guidelines do not specify an exact endpoint for extended DAPT beyond 12 months, but a reasonable approach is to continue DAPT indefinitely as long as the patient remains free of bleeding complications, with annual reassessment for changes in bleeding risk, medication tolerance, and ischemic risk profile 8, 11
  • Consider discontinuation of DAPT only if high bleeding risk develops, such as need for oral anticoagulation, significant overt bleeding, or major surgery planned 8, 9, 10

Common Pitfalls to Avoid

  • Do not automatically discontinue DAPT at 12 months in high-risk patients who have tolerated therapy well, as this increases thrombotic risk 8
  • Do not use aspirin doses >100 mg daily when combined with a P2Y12 inhibitor, as this increases bleeding without improving efficacy 8, 10
  • Do not fail to assess bleeding risk factors at each visit, as development of new bleeding risk may warrant DAPT modification 8, 9

Continuation of Antithrombotic Therapy After 3 Years of Brilique

Standard Regimen After Completion of DAPT

  • The American College of Cardiology and European Society of Cardiology recommend continuation of aspirin 75-100 mg daily for life after completion of the recommended period of dual antiplatelet therapy (DAPT) 13
  • Patients who have completed 3 years of ticagrelor therapy have exceeded the minimum recommended period of 12 months of DAPT for acute coronary syndromes or 6 months for stable coronary artery disease 13

Considerations for Extending DAPT Beyond 3 Years

  • Patients with high thrombotic risk may benefit from continued DAPT with ticagrelor 60 mg twice daily plus aspirin, if they meet certain criteria, including complex coronary artery disease and at least one additional risk factor, such as prior myocardial infarction, chronic kidney disease, or history of stent thrombosis 14
  • The European Heart Society recommends that patients with high thrombotic risk and low bleeding risk be considered for continued DAPT with ticagrelor 60 mg twice daily plus aspirin, with a strength of evidence classified as Class IIa 14

Dosage Reduction for Prolonged Therapy

  • Ticagrelor 60 mg twice daily (not 90 mg) is the approved dose for long-term secondary prevention after myocardial infarction, demonstrating similar efficacy with a lower risk of bleeding 14

Decision Algorithm

  • Evaluate the risk of bleeding: if the patient has had major bleeding in the past 3 years, stop ticagrelor and continue aspirin only 13
  • Evaluate the risk of thrombosis: if the patient has complex coronary artery disease and additional risk factors, consider continuing ticagrelor 60 mg twice daily plus aspirin 14

Common Pitfalls to Avoid

  • Do not continue ticagrelor 90 mg twice daily for prolonged therapy beyond 12 months - the approved dose for long-term secondary prevention is 60 mg twice daily 14
  • Do not use aspirin doses >100 mg daily in combination with ticagrelor, as this increases the risk of bleeding without additional benefit 13
  • Do not stop aspirin abruptly after stopping ticagrelor - aspirin should be continued for life 13
  • Do not ignore annual evaluation of bleeding risk and thrombotic risk to decide on continuation or discontinuation of DAPT 14

REFERENCES